EarlsMF. The committee on psychosocial aspects of child and family health. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics, 2010; 126:1032–1039.
4.
SlomianJ, HonvoG, EmontsP, ReginsterJ-Y, BruyèreO. Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes. Womens Health, 2019; 15:1745506519844044.
5.
GavinNI, GaynesBN, LohrKN, Meltzer-BrodyS, GartlehnerG, SwinsonT. Perinatal depression: A systematic review of prevalence and incidence. Obstet Gynecol, 2005; 106:1071–1083.
6.
DeligiannidisKM, Kroll-DesrosiersAR, MoS, et al.Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression. Psychoneuroendocrinology, 2016; 70:98–107.
7.
MelónLC, HooperA, YangX, MossSJ, MaguireJ. Inability to suppress the stress-induced activation of the HPA axis during the peripartum period engenders deficits in postpartum behaviors in mice. Psychoneuroendocrinology, 2018; 90:182–193.
8.
OsborneLM, GispenF, SanyalA, YenokyanG, MeilmanS, PayneJL. Lower allopregnanolone during pregnancy predicts postpartum depression: An exploratory study. Psychoneuroendocrinology, 2017; 79:116–121.
9.
FDA approves first treatment for post-partum depression. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm Accessed April17, 2019.
10.
SeppalaLJ, WermelinkA, de VriesM, et al.Fall-risk-increasing drugs: A systematic review and meta-analysis: II. Psychotropics. J Am Med Dir Assoc, 2018; 19:371.e11–371.e17.
11.
RizzoliR, CooperC, ReginsterJY, et al.Antidepressant medications and osteoporosis. Bone, 2012; 51:606–613.
12.
GebaraMA, LipseyKL, KarpJF, et al.Cause or effect? Selective serotonin reuptake inhibitors and falls in older adults: A systematic review. Am J Geriatr Psychiatry, 2015; 23:1016–1028.
